Skip to main content
OpenTrials
Completed

NCT Number: NCT02724358

Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Aortic Valve Disease Bicuspid Aortic Valve Disease Carcinoma Carcinoma, Hepatocellular Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Digestive System Neoplasms Heart Defects, Congenital Heart Diseases Heart Valve Diseases Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Notch1 Rg3 TACE

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, 200438, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically confirmed hepatocellular carcinoma.
  • High expression of Notch1 in tumor tissues.

Exclusion criteria

no pathological evidence of HCC

Treatment and study plan

TACE

Procedure

iodized oil (5ml) + Pirarubicin (20mg)

Other names: Transcatheter Arterial Chemoembolization

Rg3

Drug

20mg, BID, maintained though Month 12.

TACE + Rg3

Other

protective therapy

Procedure

standard liver protective therapy

Primary outcomes

  1. Overall Survival

    Time frame: 3 years

  2. Time to progression

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Eastern Hepatobiliary Surgery Hospital

Other

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2015
First posted
Mar 31, 2016
Registry last updated
Mar 31, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.